GENOME & COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10,190 KRW | +4.41% |
|
+14.24% | -18.41% |
| Sales 2022 | 14.08B 10.31M | Sales 2023 | 14.3B 10.46M | Capitalization | 176B 129M |
|---|---|---|---|---|---|
| Net income 2022 | -51.84B -37.95M | Net income 2023 | -47.47B -34.75M | EV / Sales 2022 | 10.3 x |
| Net cash position 2022 | 100B 73.5M | Net cash position 2023 | 59.82B 43.79M | EV / Sales 2023 | 8.14 x |
| P/E ratio 2022 |
-4.74
x | P/E ratio 2023 |
-3.72
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 65.8% |
More Fundamentals
* Assessed data
More news
| 1 day | +4.41% | ||
| 1 week | +14.24% | ||
| Current month | +47.47% | ||
| 1 month | +55.34% | ||
| 3 months | +12.85% | ||
| 6 months | -19.06% | ||
| Current year | -18.41% |
1 week
7 720.00
10 340.00
1 month
6 770.0010 340.00
Current year
6 550.0013 850.00
1 year
6 550.0019 520.00
3 years
6 550.0057 600.00
5 years
6 550.0095 000.00
10 years
6 550.0095 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Han-Su Park
CEO | Chief Executive Officer | 51 | 15-09-23 |
Ji-Soo Bae
FOU | Founder | 53 | 15-09-23 |
Young-Jin Seo
BRD | Director/Board Member | 44 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byeong-Geon Lee
BRD | Director/Board Member | 67 | - |
Ji-Soo Bae
FOU | Founder | 53 | 15-09-23 |
Han-Su Park
CEO | Chief Executive Officer | 51 | 15-09-23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 10,190 | +4.41% | 432,613 |
| 24-05-27 | 9,760 | +20.94% | 1,598,678 |
| 24-05-24 | 8,070 | -4.83% | 194,567 |
| 24-05-23 | 8,480 | -2.08% | 41,200 |
| 24-05-22 | 8,660 | -2.91% | 82,011 |
End-of-day quote Korea S.E., May 27, 2024
More quotes
Genome&Company is a company mainly engaged in the research, development, manufacturing and sale of probiotics. Probiotics are mainly used in products including immune oncology therapeutic supplements, dietary supplements, cosmetics and medicines. These products are mainly applied to obesity, diabetes, acne, atopic dermatitis, and cancer complementary therapies.
Calendar
2024-08-25
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -18.41% | 113M | |
| +54.05% | 58.71B | |
| -2.02% | 41.31B | |
| +36.50% | 39.2B | |
| -10.22% | 27.4B | |
| +13.42% | 26.55B | |
| -21.60% | 18.98B | |
| +2.89% | 12.51B | |
| +22.40% | 11.94B | |
| +27.49% | 12.08B |
- Stock Market
- Equities
- A314130 Stock
